Iradian Corporation reported second quarter 2026 financial results, announcing revenue of $20.5 million and GAAP diluted earnings per share of $0.41. The company declared a regular quarterly cash dividend of $0.20 per share, payable on August 28, 2026 to shareholders of record as of August 14, 2026. Management reaffirmed full-year 2026 revenue guidance of $91.0 million to $96.0 million and provided third-quarter revenue expectations of $23.0 million to $24.5 million. Iradian Corporation is a leader in developing innovative magnetic resonance imaging compatible medical devices.

Iradimed Corporation reported second quarter 2026 financial results, announcing revenue of $20.5 million and GAAP diluted EPS of $0.41 for the three months ended June 30, 2026. The company declared a regular quarterly cash dividend of $0.20 per share, payable on August 28, 2026 to stockholders of record as of August 14, 2026. Management reaffirmed full-year 2026 revenue guidance of $91.0 million to $96.0 million and provided third-quarter revenue expectations of $23.0 million to $24.5 million. Iradimed Corporation is a leader in developing innovative magnetic resonance imaging compatible medical devices.